[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![USCorpFilings Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1859110030752313345.png) SEC Filings Digest [@USCorpFilings](/creator/twitter/USCorpFilings) on x 4400 followers
Created: 2025-06-13 11:30:09 UTC

$ARVN Product Expansion:

On June 13, 2025, Arvinas, Inc. reported promising preclinical data for its investigational drug ARV-393 targeting multiple forms of B-cell lymphoma, demonstrating significant tumor reduction and enhanced effectiveness when combined with other therapies at the EHA 2025 Congress in Milan, Italy.




XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1933487048062558216/c:line.svg)

**Related Topics**
[italy](/topic/italy)
[milan](/topic/milan)
[promising](/topic/promising)
[sec](/topic/sec)
[$arvn](/topic/$arvn)

[Post Link](https://x.com/USCorpFilings/status/1933487048062558216)